TY - JOUR
T1 - Boosting NAD+ with a small molecule that activates NAMPT
AU - Gardell, Stephen J.
AU - Hopf, Meghan
AU - Khan, Asima
AU - Dispagna, Mauro
AU - Hampton Sessions, E.
AU - Falter, Rebecca
AU - Kapoor, Nidhi
AU - Brooks, Jeanne
AU - Culver, Jeffrey
AU - Petucci, Chris
AU - Ma, Chen Ting
AU - Cohen, Steven E.
AU - Tanaka, Jun
AU - Burgos, Emmanuel S.
AU - Hirschi, Jennifer S.
AU - Smith, Steven R.
AU - Sergienko, Eduard
AU - Pinkerton, Anthony B.
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Pharmacological strategies that boost intracellular NAD+ are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD+ precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+. Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD+ and realize its associated salutary effects.
AB - Pharmacological strategies that boost intracellular NAD+ are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD+ precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+. Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD+ and realize its associated salutary effects.
UR - http://www.scopus.com/inward/record.url?scp=85069435068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069435068&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-11078-z
DO - 10.1038/s41467-019-11078-z
M3 - Article
C2 - 31324777
AN - SCOPUS:85069435068
SN - 2041-1723
VL - 10
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 3241
ER -